The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).
 
Shalini Subramaniam
No Relationships to Disclose
 
Guy C. Toner
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst)
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Medivation (Inst)
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Andrew James Martin
No Relationships to Disclose
 
Farzana D. Pashankar
No Relationships to Disclose
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Janssen-Cilag; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Janssen-Cilag; MSD Oncology; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme; Merck Sharp & Dohme; Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Mark Jeffery
No Relationships to Disclose
 
Danish Mazhar
No Relationships to Disclose
 
Robert A Huddart
Employment - Aspen Parkside Hopsital (I)
Leadership - Cancer clinic london Limited liability partnership
Honoraria - Janssen Oncology
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck Sharp & Dohme; Nektar; Roche
Speakers' Bureau - MSD; Roche; Roche
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for dug discovery from Janssen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; MSD Oncology; Nektar; Roche/Genentech
 
Euan Thomas Walpole
Consulting or Advisory Role - Novartis
Research Funding - MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
 
Amanda Gwendolyn Stevanovic
No Relationships to Disclose
 
David Wyld
Consulting or Advisory Role - Ipsen
Speakers' Bureau - Ipsen
Research Funding - Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen; Novartis
 
Fritha J. Hanning
Employment - Canopy Cancer Care
Leadership - Canopy Cancer Care
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Roche
 
Matthew James Wheater
Honoraria - Bristol-Myers Squibb; Delcath Systems; MSD; Novartis; Pfizer; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Healthcare at Home; Novartis
Research Funding - AVEO (Inst); GlaxoSmithKline/Novartis (Inst); MSD (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Jay R. Balagtas
No Relationships to Disclose
 
Simon Troon
Research Funding - Astellas Pharma (Inst); pfizer (Inst)
 
Alison Jane Birtle
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Janssen Oncology; Roche; Sanofi
Speakers' Bureau - Bayer; Janssen Oncology; Pfizer
Research Funding - Genzyme
 
Jeff D. White
No Relationships to Disclose
 
Peter S. Grimison
Research Funding - ASLAN Pharmaceuticals (Inst); Boston Biomedical (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Janssen-Cilag (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); QED Therapeutics (Inst); Specialised Therapeutics (Inst); Tigermed (Inst); Tilray (Inst)